The Women’s Tennis Association (WTA) has implemented a new rule requiring all players on the WTA Tour to undergo genetic sex testing before competing. This testing involves checking for the presence of the SRY gene, which determines male traits. Only players with a negative result indicating the absence of this gene will be allowed to participate.
Under the revised policy, players who test positive will undergo further evaluation before a final decision is made. This one-time testing is a significant change from the previous regulations that permitted transgender women to compete if they maintained low testosterone levels. The WTA aims to ensure fair competition and equal opportunities for all players in its tournaments.
The WTA emphasized that the updated policy is based on biological sex and will come into effect in 2026. This decision aligns with efforts to adapt to evolving standards in women’s sports and promote fairness in professional tennis. The governing body acknowledged the sensitivity of the issue and pledged to implement the policy with respect and consideration for all players.
Other sports organizations, such as World Athletics and World Boxing, have also introduced similar genetic testing requirements for female athletes in recent years. These measures reflect a broader trend towards ensuring fairness and integrity in competitive sports through stringent eligibility criteria.
